The U.S. government announced it has negotiated a 71% discount on Novo Nordisk’s (NVO) Ozempic and Wegovy drugs for patients in Medicare, Bloomberg’s Madison Muller reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Medicare negotiates 71% discount on Novo’s Ozempic, Wegovy, Bloomberg says
- Moderately bullish activity in Novo Nordisk with shares up 4.61%
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Novo Nordisk: Amycretin phase 2 trial reports significant weight loss
- Novo Nordisk Reports Positive Phase 2 Results for Amycretin in Type 2 Diabetes